Albright Joshua E, Stojkovska Iva, Rahman Abir A, Brown Connor J, Morrison Brad E
Department of Biological Sciences, Boise State University, Boise, ID 83725, USA.
Department of Biological Sciences, Boise State University, Boise, ID 83725, USA; Biomolecular Ph.D. program, Boise State University, Boise, ID 83725, USA.
Neurosci Lett. 2016 Feb 26;615:50-4. doi: 10.1016/j.neulet.2016.01.019. Epub 2016 Jan 20.
The primary clinical motor symptoms of Parkinson's disease (PD) result from loss of dopaminergic (DA) neurons in the substantia nigra (SN). Consequently, neurogenesis of this group of neurons in the adult brain has drawn considerable interest for the purpose of harnessing endogenous neurogenerative potential as well as devising better strategies for stem cell therapy for PD. However, the existence of adult neurogenesis for DA neurons within the SN remains controversial. To overcome technical and design limitations associated with previous studies, our group has developed a novel genetic mouse model for assessing adult nigral DA neurogenesis. This system utilizes transgenic mice that express a tamoxifen-activatable Cre recombinase (Cre(ERT2)) under the control of the neuronal progenitor cell promoters nestin or Sox2 leading to suppression of the DA neuron marker tyrosine hydroxylase (TH) via excision of exon 1 by flanking loxP sites in adult animals. This study reports that six months following initiation of a six week treatment with tamoxifen mice with nestin-mediated Th excision displayed a significant reduction in TH+ neurons in the SN. This finding indicates that nestin-expressing cells regenerate DA neurons within the SN of adult animals. Interestingly, no reduction was observed in TH+ cells following Sox2-mediated Th excision suggesting that a nestin+/SOX2- precursor cell population drives DA neurogenesis in the adult SN. This information represents a substantial leap in current knowledge of adult DA neurogenesis, will enable improved in vitro and in vivo modeling, as well as facilitate the harnessing of this process for therapeutic intervention for PD.
帕金森病(PD)的主要临床运动症状是由于黑质(SN)中多巴胺能(DA)神经元的丧失所致。因此,成人大脑中这群神经元的神经发生引起了人们极大的兴趣,目的是利用内源性神经发生潜力以及为PD设计更好的干细胞治疗策略。然而,SN内DA神经元的成体神经发生是否存在仍存在争议。为了克服与先前研究相关的技术和设计限制,我们团队开发了一种用于评估成年黑质DA神经发生的新型基因小鼠模型。该系统利用转基因小鼠,这些小鼠在神经元祖细胞启动子巢蛋白(nestin)或Sox2的控制下表达他莫昔芬激活的Cre重组酶(Cre(ERT2)),通过成年动物中侧翼loxP位点切除外显子1,导致DA神经元标记物酪氨酸羟化酶(TH)受到抑制。本研究报告称,在用他莫昔芬进行六周治疗开始六个月后,巢蛋白介导的Th切除的小鼠SN中TH+神经元显著减少。这一发现表明,表达巢蛋白的细胞在成年动物的SN内再生DA神经元。有趣的是,在Sox2介导的Th切除后,未观察到TH+细胞减少,这表明巢蛋白+/SOX2-前体细胞群体驱动成年SN中的DA神经发生。这一信息代表了当前对成年DA神经发生认识的重大飞跃,将有助于改进体外和体内模型,以及促进利用这一过程对PD进行治疗干预。